Abstract: The present invention relates to a system for measuring a micro-vascular flow distribution of a tissue portion of a mammal comprising means (101) for measuring a first indicator (MTT) for the blood flow through a capillary bed, means (102) for measuring a second indicator (CTTH) of heterogeneity of the blood flow in said capillary bed, and a first processor (110) arranged for using the first and the second indicator to estimate an extraction capacity (EC) of a substance from the blood in said capillary bed.

Abstract: The present disclosure relates to a method and a system for modelling a human heart and/or chambers and cavities therein, such as the left and right atrium, based on a plurality of emission tomography images, such as positron emission images, of said human heart, wherein each image represents concentrations of a tracer that has been injected at a specific time, the overall method comprising the steps of: A: extracting time activity curves of a tracer that has been injected for a plurality of pixels and/or voxels; B: identifying first-pass peaks of the time activity curves, each peak corresponding to an arrival time of the injected tracer at the corresponding pixel/voxel; C: defining a model comprising at least two portions of the heart, wherein the at least two portions are isolated by selecting pixels and/or voxels based on comparisons of the first-pass peaks against a threshold; and D: arranging the at least two portions in relation to each other by comparing the arrival times of the first-pass peaks of the

Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.

Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.

Abstract: A method is provided of treating, preventing or ameliorating type 2 diabetes and/or a clinical condition associated with type 2 diabetes, which method comprises administering an effective amount of cafestol or a derivative thereof including esters and salts thereof to a person in need thereof. Further provided are compositions comprising cafestol and at least one additional agent suitable for treating, preventing or ameliorating diabetes and/or a clinical condition associated with diabetes. A method is also provided of increasing insulin secretion and/or increasing insulin-dependent glucose uptake, said method comprising administering an effective amount of cafestol or a derivative thereof to a person in need thereof.

Abstract: An add-on cap for electroporation of tissue including: at least one closed sidewall, such as a cylindrical sidewall; a proximal open end; a distal open end; the at least one closed sidewall and the proximal and distal open ends defining a hollow body having an internal volume; two electrodes on opposite sides of the internal volume, the electrodes configured to apply an electric field for electroporation of tissue inside the internal volume, wherein the proximal open end is sealingly engaged to a tip of an instrument, such as an endoscope. A system for electroporation of tissue including the add-on cap and an endoscope.

Abstract: The present invention provides a positively charged co-polymer for use as an antimicrobial agent, wherein said positively charged co-polymer is composed of amino acids and/or derivatives thereof and wherein at least 75 molar percent of said amino acids are selected from the group consisting of alanine, lysine, glutamate, arginine and tyrosine and/or derivatives thereof. The present invention also provides methods for treating, preventing or ameliorating a microbial infection comprising administration of positively charged random co-polymers as well as a pharmaceutical composition comprising said co-polymer. The invention further provides a kit of parts comprising the positively charged random co-polymer.

Abstract: The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.

Abstract: The present invention concerns 3D-crystals of complexes of ribosomal S6 kinase (RSK) and mitogen- and stress-activated protein kinase (MSK) proteins and their ligands, as well as methods for crystallization, three-dimensional structure determination and structure assisted methods for identifying ligands of said proteins.

Abstract: The present invention relates to the use of isosteviol, steviol, and related compounds for elevating the plasma HDL-cholesterol level. The invention furthermore relates to the use of these compounds for reducing the body weight of a subject and/or lowering the plasma triglyceride level of a subject, including a concomitant elevation of the plasma HDL-cholesterol level. Preferably the compounds used are isosteviol and/or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. The compounds may furthermore be administered in combination with one or more further active compounds, such as e.g. LDL-cholesterol lowering agents. The invention furthermore relates to a method for elevating the plasma HDL-cholesterol level in a subject by administering to a subject in need of such treatment a plasma HDL-cholesterol level elevating amount of the compounds, described herein.

Abstract: The invention relates to the use of soluble CD206 as a general health/disease marker, and a specific marker for liver disorders, sepsis, and pneumonia.

Abstract: The present invention relates to a method for estimating a measure of a penumbra size of a penumbra in biological tissue wherein first and second images obtained respectively by perfusion weighted imaging (PWI) and diffusion weighted imaging (DWI) are analyzed, and wherein the analysis of the first image includes application of a level set method, and the analysis of the second image includes application of a grayscale morphological operation. In a further embodiment of the invention, a connected component labeling algorithm maybe applied on any one of the first and second image. The invention further relates to a system, a computer program product and use of a corresponding method.

Abstract: The present invention relates to uses and methods involving Panobinostat and HIV-1. In particular relates the present invention to Panobinostat for use in the treatment of HIV-1 and especially latent HIV-1. This is done using a low dosage of Panobinostat which is highly effective in depleting the HIV-1 reservoir.

Abstract: The present invention relates in one aspect to radiolabeled compounds comprising the structure of Formula 1. The radiolabeled compounds are preferably bile acids or bile acid derivatives. Further aspects of the invention relates to use of the compounds comprising the structure of Formula 1 in imaging methods such as for example PET, imaging method using a compound comprising the structure of Formula 1, administering said compound to an individual and making a radiographic image of a region of interest from said individual.

Abstract: An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods.

Abstract: A method of making a three-dimensional biocompatible scaffold capable of supporting cell activities such as growth and differentiation, the method includes providing a supporting grid that forms an open network and provides mechanical support of a second biocompatible material. The second biocompatible material has interconnected cavities that allow nutrients, metabolites and soluble factors to diffuse throughout the scaffold. The scaffold design can be understood as a hierarchically organised structure. At the micron to submicron length scale a top/down manufacturing approach is used to make a structure that will constitute the frame into which a bottom/up processing approach is applied to form an open porous scaffold with specific nano sized features. The advantage of this hierarchically organised design is that benefits can be drawn independently from both the micron and the nano sized structures, promoting specific cell activities and providing sufficient mechanical compliance.

Abstract: A device for biological purposes such as cell culturing, enzymatic reactions or filtering of fluid has a body with first and second surfaces. The body is delimited by a rim and an aperture in the center of the body. The aperture is covered at the first and second surface by first and second plates. The first and/or second plate has an inlet orifice allowing liquid medium into the aperture. Rotating means are arranged in the aperture between the first and second plate. At least one recessed portion is a cavity in the rim of the body having a first outlet orifice allowing the liquid medium to flow out of the body. At least one outlet channel connects the circular aperture with the recessed portion. Liquid is pumped into the aperture of the device and pumped through at least one outlet channel.

Abstract: The present invention relates to an ultrasonic system for measuring a micro-vascular flow distribution of a tissue portion of a mammal comprising an ultrasonic transducer (101) arranged for measuring a first indicator (MTT) for the blood flow through a capillary bed in the tissue portion, and arranged for measuring a second indicator of heterogeneity (CTTH, ?) of the blood flow in said capillary bed, and a processor (110) arranged for using the first (MTT) and the second (?) indicator to estimate an extraction capacity (EC) of a substance from the blood in said capillary bed.

Abstract: The present invention relates to a system for measuring a micro-vascular flow distribution of a tissue portion of a mammal comprising means (101) for measuring a first indicator (MTT) for the blood flow through a capillary bed, means (102) for measuring a second indicator (CTTH) of heterogeneity of the blood flow in said capillary bed, and a first processor (110) arranged for using the first and the second indicator to estimate an extraction capacity (EC) of a substance from the blood in said capillary bed.

Abstract: The present invention relates to a method for estimating a measure of a penumbra size of a penumbra in biological tissue wherein first and second images obtained respectively by perfusion weighted imaging (PWI) and diffusion weighted imaging (DWI) are analyzed, and wherein the analysis of the first image includes application of a level set method, and the analysis of the second image includes application of a grayscale morphological operation. In a further embodiment of the invention, a connected component labeling algorithm maybe applied on any one of the first and second image. The invention further relates to a system, a computer program product and use of a corresponding method.